• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

冠心病合并2型糖尿病患者中五聚体蛋白3水平的变化及其与代谢指标的相互作用

Changes in pentraxin-3 level and its interaction with metabolic indices in patients with coronary artery disease and type 2 diabetes mellitus.

作者信息

Kravchun Pavlo G, Kadykova Olga I, Molotyagin Dmitry G

机构信息

Kharkiv National Medical University, Kharkiv, Ukraine.

出版信息

Wiad Lek. 2019;72(2):181-185.

PMID:30903769
Abstract

OBJECTIVE

Introduction: Recently great attention is paid to studying of coronary artery disease (CAD) pathogenesis against the background of the diabetes mellitus (DM). First of all, the question of an inflammatory component role in development of atherosclerosis in patients with DM 2 types is studied. One of new perspective markers of immune inflammation is pentraxin-3 (PTX-3). The aim of the study was to evaluate the nature of changes in the level of pentraxin-3 in patients with coronary artery disease, depending on the presence of type 2 diabetes mellitus and to investigate the nature of the relationship with metabolic parameters.

PATIENTS AND METHODS

Materials and methods: Comprehensive examination of 110 patients with CAD was conducted. Patients were divided into groups depending on presence of type 2 DM: to the first group (n = 75) entered patients with CAD and type 2 DM , the group of comparison was made by 35 patients with CAD without type 2 DM. 25 almost healthy persons entered into control group.

RESULTS

Results: As a result of a research it is established the reliable increase in PTX-3 level in all patients with CAD in comparison with group of control for 65.40% . And in the conditions of the combined current of CAD and type 2 DM, PTX-3 level is for 80.14% higher, than in persons of control group. Also interrelation between PTX-3 and indicators of dcarbohydrate and lipidic exchanges were defines. According to the carried-out correlation analysis there was revealed existence of direct integral probable connections between PTX-3 level and levels of glucose (r = 0.41; p <0,05), insulin (r = 0.36; p <0,05), index of HOMA (r = 0.89; p <0,05), TG level (r = 0.74; p <0,05) and the return with the HDL (r = - 0.54; p <0,05).

CONCLUSION

Conclusions: In patients with CAD with the accompanying type 2 DM it is established higher PTX-3 level, than in patients without type 2 DM and control group that demonstrates autoimune link activation. In the examined patients PTX-3 level increase was associated with violation of lipid and carbohydrate exchanges.

摘要

目的

引言:近年来,糖尿病(DM)背景下冠状动脉疾病(CAD)发病机制的研究备受关注。首先,研究了炎症成分在2型糖尿病患者动脉粥样硬化发展中的作用。免疫炎症的新的潜在标志物之一是五聚体-3(PTX-3)。本研究的目的是评估冠心病患者中五聚体-3水平变化的性质,取决于2型糖尿病的存在情况,并研究其与代谢参数的关系性质。

患者与方法

材料与方法:对110例CAD患者进行了全面检查。根据2型糖尿病的存在情况将患者分为几组:第一组(n = 75)为患有CAD和2型糖尿病的患者,对照组为35例无2型糖尿病的CAD患者。25名几乎健康的人进入对照组。

结果

结果:研究结果表明,与对照组相比,所有CAD患者的PTX-3水平可靠地升高了65.40%。在CAD和2型糖尿病合并存在的情况下,PTX-3水平比对照组高80.14%。还确定了PTX-3与碳水化合物和脂质交换指标之间的相互关系。根据进行的相关性分析,发现PTX-3水平与血糖水平(r = 0.41;p <0.05)、胰岛素水平(r = 0.36;p <0.05)、HOMA指数(r = 0.89;p <0.05)、甘油三酯水平(r = 0.74;p <0.05)以及与高密度脂蛋白的相关性(r = -0.54;p <0.05)之间存在直接的整体可能联系。

结论

结论:在伴有2型糖尿病的CAD患者中,PTX-3水平高于无2型糖尿病的患者和对照组,这表明自身免疫联系被激活。在受检患者中,PTX-3水平升高与脂质和碳水化合物交换的紊乱有关。

相似文献

1
Changes in pentraxin-3 level and its interaction with metabolic indices in patients with coronary artery disease and type 2 diabetes mellitus.冠心病合并2型糖尿病患者中五聚体蛋白3水平的变化及其与代谢指标的相互作用
Wiad Lek. 2019;72(2):181-185.
2
Serum pentraxin 3 levels are associated with the complexity and severity of coronary artery disease in patients with stable angina pectoris.血清五聚素 3 水平与稳定性心绞痛患者冠状动脉疾病的复杂性和严重程度相关。
J Investig Med. 2013 Feb;61(2):278-85. doi: 10.2310/JIM.0b013e31827c2971.
3
The serum pentraxin-3 is elevated in patients with cardiac syndrome X.心脏X综合征患者的血清五聚体蛋白3水平升高。
Turk Kardiyol Dern Ars. 2013 Jun;41(4):290-5. doi: 10.5543/tkda.2013.20025.
4
Comparison of cystatin-C and pentraxin-3 in coronary atherosclerosis.胱抑素-C与五聚素-3在冠状动脉粥样硬化中的比较。
Coron Artery Dis. 2014 Nov;25(7):589-94. doi: 10.1097/MCA.0000000000000132.
5
Changes in the inflammatory markers with advancing stages of diabetic nephropathy and the role of pentraxin-3.糖尿病肾病进展阶段炎症标志物的变化及五聚素3的作用
Ren Fail. 2016 Sep;38(8):1193-8. doi: 10.1080/0886022X.2016.1209031. Epub 2016 Jul 19.
6
Association of plasma pentraxin-3 levels with coronary risk factors and the lipid profile: a cross-sectional study in Japanese patients with stable angina pectoris.血浆五聚体蛋白3水平与冠心病危险因素及血脂谱的关联:一项针对日本稳定型心绞痛患者的横断面研究。
Heart Vessels. 2018 Nov;33(11):1301-1310. doi: 10.1007/s00380-018-1191-8. Epub 2018 May 22.
7
Serum Pentraxin-3 Level in Patients Who Underwent Coronary Angiography and Relationship with Coronary Atherosclerosis.接受冠状动脉造影患者的血清五聚体-3水平及其与冠状动脉粥样硬化的关系
Med Princ Pract. 2015;24(4):369-75. doi: 10.1159/000381879. Epub 2015 May 5.
8
Association of Plasma Pentraxin-3 Levels with Retinopathy and Systemic Factors in Diabetic Patients.糖尿病患者血浆五聚体蛋白3水平与视网膜病变及全身因素的关联
Metab Syndr Relat Disord. 2018 Sep;16(7):358-365. doi: 10.1089/met.2018.0023. Epub 2018 Jul 23.
9
Serum high-sensitivity C-reactive protein and lipoprotein(a) levels: a comparison between diabetic and non-diabetic patients with coronary artery disease.血清高敏C反应蛋白和脂蛋白(a)水平:糖尿病与非糖尿病冠心病患者的比较
Med J Malaysia. 2011 Jun;66(2):113-6.
10
[Metabolic, inflammatory and imaging biomarkers in evaluation of coronary atherosclerosis severity in patients with coronary artery disease and diabetes mellitus type 2].[代谢、炎症和影像学生物标志物在评估冠心病合并2型糖尿病患者冠状动脉粥样硬化严重程度中的应用]
Ter Arkh. 2021 Sep 15;93(9):1030-1036. doi: 10.26442/00403660.2021.09.201032.

引用本文的文献

1
Pentraxin 3 Levels in Young Women with and without Polycystic Ovary Syndrome (PCOS) in relation to the Nutritional Status and Systemic Inflammation.患有和未患有多囊卵巢综合征(PCOS)的年轻女性中,与营养状况和全身炎症相关的五聚体3水平
Int J Endocrinol. 2020 Sep 2;2020:1380176. doi: 10.1155/2020/1380176. eCollection 2020.